Merck/AstraZeneca Stay Tied To Each Other For Another Two Years
This article was originally published in The Pink Sheet Daily
Merck and AstraZeneca continue a 30-year partnership after coming to terms that could benefit both companies.
You may also be interested in...
The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.
With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.
By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.